FeesSafety
Pluang+

Hyperliquid hits $713M revenue as it expands beyond crypto with new financial partnerships.

Market News
03 Nov 2026, 14:27 WIB
Altcoin Buzz
View Source
Bullish
Hyperliquid hits $713M revenue as it expands beyond crypto with new financial partnerships.

Hyperliquid generated about $713 million in revenue over the past year, driven by its expanding trading infrastructure now supporting traditional assets like stocks and commodities. Its HIP-3 framework enables third-party operators to build markets, attracting major firms like ICE, which plans a regulated U.S. market using Hyperliquid tech pending approvals. Despite growth in new markets, recent quarterly revenue shows a slower pace, highlighting challenges in sustaining momentum and regulatory hurdles in the U.S. The platform aims to become a key financial infrastructure provider beyond crypto, focusing on execution while partners handle market operations and compliance.

Hyperliquid's reported $713 million revenue provides context for readers interested in emerging financial technologies. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Nov 03, 2026 19:03 WIB: out of 50 priced major cryptocurrencies, 12 rose and 37 fell today. Notable movers include EOS (EOS.IO) at Rp12.649 with an 8.13% increase and a typical hold time of 87 days, CRV (Curve DAO Token) at Rp4.721 down 5.07% with a 60% sell order activity, and BAT (Basic Attention Token) at Rp2.296 down 4.09% with a 95% buy order activity and a typical hold time of 93 days.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
47 minutes ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
47 minutes ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
47 minutes ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
1 hour ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App